Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Ghasem Ghalamfarsa, Mahmoud Mahmoudi, Mousa Mohammadnia-Afrouzi, Yaghoub Yazdani, Enayat Anvari, Abolghasem Hadinia, Amir Ghanbari, Maryam Setayesh, Mehdi Yousefi & Farhad Jadidi-Niaragh. (2016) IL-21 and IL-21 receptor in the immunopathogenesis of multiple sclerosis. Journal of Immunotoxicology 13:3, pages 274-285.
Read now
Read now
Rachel Babij & Jai S Perumal. (2015) Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis. Neuropsychiatric Disease and Treatment 11, pages 1221-1229.
Read now
Read now
Benjamin Knier, Bernhard Hemmer & Thomas Korn. (2014) Novel monoclonal antibodies for therapy of multiple sclerosis. Expert Opinion on Biological Therapy 14:4, pages 503-513.
Read now
Read now
Óscar Fernandez. (2014) Alemtuzumab in the treatment of multiple sclerosis. Journal of Inflammation Research 7, pages 19-27.
Read now
Read now
Patricia Katherine Coyle. (2014) Current evaluation of alemtuzumab in multiple sclerosis. Expert Opinion on Biological Therapy 14:1, pages 127-135.
Read now
Read now
Articles from other publishers (19)
Oliver A Leach, David A Hilton, William Adams, Seth Love & Agne Straukiene. (2020) Alemtuzumab-related eosinophilic central nervous system vasculitis. Multiple Sclerosis Journal 26:12, pages 1602-1606.
Crossref
Crossref
Maria V. Pinto & Adelaide Fernandes. (2020) Microglial Phagocytosis—Rational but Challenging Therapeutic Target in Multiple Sclerosis. International Journal of Molecular Sciences 21:17, pages 5960.
Crossref
Crossref
Carmen Alcalá, F. Gascón, Francisco Pérez-Miralles, J. A. Domínguez, S. Gil-Perotín & B. Casanova. (2019) Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing–remitting multiple sclerosis is effective and safe. Journal of Neurology 266:3, pages 726-734.
Crossref
Crossref
Yara Dadalti Fragoso, Tarso Adoni, Joseph B. Bidin Brooks, Alessandro Finkelsztejn, Paulo Diniz da Gama, Anderson K. Grzesiuk, Vanessa Daccach Marques, Monica Fiuza K. Parolin, Henry K. Sato, Daniel Lima Varela & Claudia Cristina F. Vasconcelos. (2018) Practical Evidence-Based Recommendations for Patients with Multiple Sclerosis Who Want to Have Children. Neurology and Therapy 7:2, pages 207-232.
Crossref
Crossref
Floriana De Angelis, Domenico Plantone & Jeremy Chataway. (2018) Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview. CNS Drugs 32:6, pages 499-526.
Crossref
Crossref
Antònia Agustí Escasany. (2018) Reporting suspected adverse reactions to new commercialized medicines in real world. Multiple Sclerosis Journal 24:6, pages 816-817.
Crossref
Crossref
Jian Zhang, Shengliang Shi, Yueling Zhang, Jiefeng Luo, Yousheng Xiao, Lian Meng & Xiaobo Yang. (2017) alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis. Cochrane Database of Systematic Reviews 2018:5.
Crossref
Crossref
Lina Hassoun, Judith Eisele, Katja Thomas & Tjalf Ziemssen. (2016) Hands on Alemtuzumab-experience from clinical practice: whom and how to treat. Multiple Sclerosis and Demyelinating Disorders 1:1.
Crossref
Crossref
Carlo Selmi, Jobert G. Barin & Noel R. Rose. (2016) Current trends in autoimmunity and the nervous system. Journal of Autoimmunity 75, pages 20-29.
Crossref
Crossref
Dirk Smeets, Annemie Ribbens, Diana M. Sima, Melissa Cambron, Dana Horakova, Saurabh Jain, Anke Maertens, Eline Van Vlierberghe, Vasilis Terzopoulos, Anne‐Marie Van Binst, Manuela Vaneckova, Jan Krasensky, Tomas Uher, Zdenek Seidl, Jacques De Keyser, Guy Nagels, Johan De Mey, Eva Havrdova & Wim Van Hecke. (2016) Reliable measurements of brain atrophy in individual patients with multiple sclerosis. Brain and Behavior 6:9.
Crossref
Crossref
Lynn McEwan, Christina Caon, Carol Chieffe, Lori Mayer, Toni Saldana-King & Colleen E. Miller. (2016) Best Practices in Alemtuzumab Administration. Journal of Infusion Nursing 39:2, pages 93-104.
Crossref
Crossref
Ø. Torkildsen, K.‐M. Myhr & L. Bø. (2015) Disease‐modifying treatments for multiple sclerosis – a review of approved medications. European Journal of Neurology 23:S1, pages 18-27.
Crossref
Crossref
Paolo Pellegrino, Carla Carnovale, Valentina Perrone, Marco Pozzi, Stefania Antoniazzi, Sonia Radice & Emilio Clementi. (2014) Efficacy of vaccination against influenza in patients with multiple sclerosis: The role of concomitant therapies. Vaccine 32:37, pages 4730-4735.
Crossref
Crossref
Alan M. Palmer. (2014) New and emerging immune-targeted drugs for the treatment of multiple sclerosis. British Journal of Clinical Pharmacology 78:1, pages 33-43.
Crossref
Crossref
Oscar Fernandez. (2014) BG-12 (dimethyl fumarate) in the treatment of multiple sclerosis. Clinical Investigation 4:5, pages 441-451.
Crossref
Crossref
Kathrin Thell, Roland Hellinger, Gernot Schabbauer & Christian W. Gruber. (2014) Immunosuppressive peptides and their therapeutic applications. Drug Discovery Today 19:5, pages 645-653.
Crossref
Crossref
Karly P. Garnock-Jones. (2014) Alemtuzumab: A Review of Its Use in Patients with Relapsing Multiple Sclerosis. Drugs 74:4, pages 489-504.
Crossref
Crossref
Jian Zhang, Yousheng Xiao, Lian Meng, Xiaobo Yang & Shengliang Shi. (2014) Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Gerd R. Burmester, Eugen Feist & Thomas Dörner. (2013) Emerging cell and cytokine targets in rheumatoid arthritis. Nature Reviews Rheumatology 10:2, pages 77-88.
Crossref
Crossref